The estimated Net Worth of Joann A Reed is at least $1.37 Million dollars as of 9 November 2023. Ms. Reed owns over 10,025 units of Mallinckrodt Plc stock worth over $22,321 and over the last 19 years she sold MNK stock worth over $929,556. In addition, she makes $420,000 as Independent Director at Mallinckrodt Plc.
JoAnn has made over 17 trades of the Mallinckrodt Plc stock since 2016, according to the Form 4 filled with the SEC. Most recently she exercised 10,025 units of MNK stock worth $880,396 on 9 November 2023.
The largest trade she's ever made was exercising 25,000 units of Mallinckrodt Plc stock on 3 May 2017 worth over $1,008,500. On average, JoAnn trades about 1,766 units every 45 days since 2006. As of 9 November 2023 she still owns at least 65,651 units of Mallinckrodt Plc stock.
You can see the complete history of Ms. Reed stock trades at the bottom of the page.
JoAnn A. Reed is Independent Director of Mallinckrodt Public Limited Company. Ms. Reed is a healthcare services consultant. Ms. Reed served as an advisor to the Chief Executive Officer of Medco Health Solutions, a leading pharmacy benefit manager, from April 2008 to April 2009. She previously served as the Senior Vice President, Finance and Chief Financial Officer of Medco until 2008. Upon joining Medco in 1988, Ms. Reed served in finance and accounting roles of increasing responsibility and was appointed Senior Vice President, Finance in 1992 and Chief Financial Officer in 1996. Prior to joining Medco, Ms. Reed’s experience included finance roles at Aetna/American Reinsurance Co., CBS Inc., Standard and Poor’s Corporation and Unisys/Timeplex Inc. Ms. Reed has been a director of American Tower Corporation since 2007 and a director of Waters Corporation since 2006. She served as a director of Health Management Associates, Inc. from 2013 to 2014 and as a trustee of St. Mary’s College of Notre Dame from 2006 to 2015. Ms. Reed’s qualifications to serve on our Board include her experience as a healthcare services consultant and her financial expertise and knowledge of financial statements, corporate finance and accounting matters.
As the Independent Director of Mallinckrodt Plc, the total compensation of JoAnn Reed at Mallinckrodt Plc is $420,000. There are 7 executives at Mallinckrodt Plc getting paid more, with Mark Trudeau having the highest compensation of $14,610,800.
JoAnn Reed is 64, she's been the Independent Director of Mallinckrodt Plc since 2013. There are 2 older and 9 younger executives at Mallinckrodt Plc. The oldest executive at Mallinckrodt Plc is J. Martin Carroll, 70, who is the Independent Director.
Joann's mailing address filed with the SEC is 116, Huntington Avenue, Back Bay, Boston, Suffolk County, Massachusetts, 02116, United States.
Over the last 11 years, insiders at Mallinckrodt Plc have traded over $29,853,069 worth of Mallinckrodt Plc stock and bought 2,559,592 units worth $174,429,961 . The most active insiders traders include & Co. Inc. Paulson, James E Deerfield Mgmt L.P...., and Nancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of $10,061. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth $9,495.
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
Mallinckrodt Plc executives and other stock owners filed with the SEC include: